BiomedGrid

  Why Does Covid-19/SARS-CoV2 Spread all Over the Whole World? Is Migration Bat Wrong or Bird Wrong? Abstract This type of lung virus infection tends to spread quickly. This virus is a highly contagious disease. Although early analysis of the disease indicated that the virus first appeared in Wuhan, this claim has not been fully confirmed by researchers. COVID-19 may be closely related to the spread of contact between humans and animals. The possibility of the virus is a mutational infection. The host of viruses that are currently believed to infect humans is bats. This is different from the 2002 new type of coronavirus, also known as SARS or atypical pneumonia virus, but it comes from the same SARS-CoV and becomes the 2019 new type of coronavirus (SARS-CoV2). However, novel SARS-CoV2 is from bats migration. The infection is caused by contact between humans and bats, it is worthy of discussion. Keywords:  COVID-19; Novel SARS-coV2; Bats Migration; Mutational Infection Abbreviations:  P

  A Success Story of Complicated Antipartum Hemorrage and Placenta Previa in ICU Setting Abstract Objective : The objective of this publication is to describe how pharmacogenomic testing can help reduce the incidence of ADEs. Summary:  Pharmacogenomic testing identifies genetic variants that help clinicians determine an individual’s expected response to medications. Results from pharmacogenomic testing may provide valuable information on the expected response to a drug while on the other hand, results may also help explain adverse drug events (ADEs), identify patients who may require closer monitoring to avoid ADEs, and avoid specific drugs that are expected to cause ADEs in certain individuals. Many ADEs are believed to have a genetic component. Drugs administered at normal doses may interact with a gene that has a genetic variant affecting the drug’s response. Pharmacogenomic testing can identify genetic variants that encode specific CYP enzymes (e.g., CYP2C9, CYP2C19, CYP2D6, and CY

  Utilizing Pharmacogenomics to Reduce Adverse Drug Events Abstract Objective : The objective of this publication is to describe how pharmacogenomic testing can help reduce the incidence of ADEs. Summary:  Pharmacogenomic testing identifies genetic variants that help clinicians determine an individual’s expected response to medications. Results from pharmacogenomic testing may provide valuable information on the expected response to a drug while on the other hand, results may also help explain adverse drug events (ADEs), identify patients who may require closer monitoring to avoid ADEs, and avoid specific drugs that are expected to cause ADEs in certain individuals. Many ADEs are believed to have a genetic component. Drugs administered at normal doses may interact with a gene that has a genetic variant affecting the drug’s response. Pharmacogenomic testing can identify genetic variants that encode specific CYP enzymes (e.g., CYP2C9, CYP2C19, CYP2D6, and CYP3As). It is estimated that dr

  Sildenafil Slows Gastric Emptying in Patients with Previously Diagnosed Diabetic Gastroparesis Abstract Objective : Delayed gastric emptying is a common complication of diabetes. Animal studies suggest that inhibition of phosphodiesterase type- 5 receptors with sildenafil improves pyloric nitric oxide availability and reverses gastroparesis in murine models of diabetic gastroparesis. We hypothesized that a single dose of sildenafil would improve gastric emptying in diabetic subjects with gastroparesis. Design:  Thirteen subjects with diabetes and gastroparesis were admitted to the UNM General Clinical Research Center on two occasions at least one week apart. Gastric motility agents were withheld 48 hours prior to study. Overnight glycemia was stabilized with infusion of intravenous insulin. At 0800, subjects ingested either 50 mg of sildenafil or matching placebo in a randomized, double blind, crossover protocol. Gastric emptying was determined using radionuclide scintigraphy followi

  Full Blood Count Estimation Using Abbott Cell-Dyn Ruby 5-Parts in Comparison with Boule Medonic M-Series 3-Parts Differential Haematology Analyser Abstract Full Blood Count (FBC) is a significant laboratory investigation often requested in clinical care and trials; laboratories should have comparable alternative methods for this test to ensure uninterrupted services. This study evaluated to what extent the Abbott CELL-DYN Ruby and Boule Medonic M-series haematology analysers can be used interchangeably. Using 110 leftover EDTA blood samples to test twelve haematological parameters, correlations and bias between the two analysers for each blood parameter were determined by plotting Passing & Bablok and Bland-Altman’s plots respectively. The two analysers were assessed comparable for a test when the bias with the 95% CI falls within the clinically acceptable limits which had been defined a priori. All the twelve FBC parameters showed strong positive correlations between the measure